Xenon Pharmaceuticals Inc.’s Post

#News: Bristol Myers Squibb will buy #CNS drugmaker Karuna Therapeutics for cash in a deal valued at $14 billion, the companies announced Friday morning. The move comes a few weeks after AbbVie signed its own $8.7 billion deal for a #neuroscience drugmaker, the further behind Cerevel Therapeutics. Both are developing a new type of #schizophrenia drug, with the FDA set to decide on #Karuna’s #KarXT by Sept. 26, 2024, while #Cerevel is in late-stage clinical trials. The acquisition, the second largest of the year after Pfizer’s completed $43 billion Seagen move, comes a few months after #BMS splurged on #cancerbiotech Mirati Therapeutics, spending up to $5.8 billion to get in on the KRAS race against Amgen. The $330 per-share $KRTX deal is a 53% premium over Karuna’s closing price on Dec. 21. The companies expect the deal to close in the first half of 2024. Karuna and Cerevel are part of a growing wave of #biotechs looking to treat schizophrenia, #depression and other #neuropsychiatric conditions as the field gets a boon in investor interest for the likes of Neumora, MapLight Therapeutics, Inc., Rapport Therapeutics and others. Karuna’s KarXT is at the FDA’s door for schizophrenia and could reach as high as $6 billion in sales, analysts have estimated. It’s also being studied for #Alzheimersdisease psychosis. If approved, it’d mark the first new type of schizophrenia drug in decades. Read more from Endpoints News 👇🏼

Neurocrine Biosciences is discontinuing two mid-stage developmental programs after their partnered drug candidates for major depressive disorder (MDD) and focal onset seizures (FOS) failed in trials. The partnered drug NBI-1065846 with Takeda did not reduce MDD in patients, while NBI-921352 with Xenon Pharmaceuticals did not demonstrate a significant decrease in seizures. However, Neurocrine is redirecting its focus on market opportunities for NBI-921352 in treating SCN8A developmental and epileptic encephalopathy syndrome.</div><div class="read-more"><a href="" class="more-link">Continue reading</a>https://lnkd.in/gfrWEywX

Role of NMDA Receptors in Neuropathic Pain N-Methyl-D-Aspartate (NMDA) receptor is a G-protein coupled ionotropic glutamate receptor. Just recently, NMDA receptors, particularly those located on the dorsal horn of the spinal cord have been discovered to be associated with an uncommon neurotoxicity leading to neuropathy. Presynaptic NMDA receptors stimulate the release of neurotransmitters like glutamate and substance P from primary afferent terminals. The synaptic glutamate then activates metabotropic glutamate receptor and AMPA receptor which results in nerve injury and neuropathic pain. NMDA receptors antagonists such as ketamine, methadone, memantine, dextromethorphan have be reported to be beneficial in the treatment of neuropathic pain.  To read more: https://lnkd.in/dKQbimc3 #pharmaceuticalsciences #pharmacyresearch #noveltherapies

Did you catch our latest BioBreakthroughs yesterday? We won't even tell you it's a must listen, cause you know it is. Marcio Souza, CEO of Praxis Precision Medicines, Inc., shares insights on revolutionizing CNS drug development. Praxis is paving the way for groundbreaking CNS (central nervous system) treatments with their patient-centric and genetics-inspired approach. Thanks to Sage Growth Partners for being our partner in this episode. #CNSDrugDevelopment #BiotechInnovation #SoHCPodcasts

The FDA advisory rejection of #Lykos MDMA therapeutic last week, closely followed by the unanimous “yes” on the efficacy and benefit of #Lilly ‘s #donanemab illustrates the stop/start nature of progress in CNS innovation, something we covered in our white paper on the new CNS market here- worth a read to get the bigger picture on this rapidly developing market. https://lnkd.in/gamddXiF

A New and Completely Different Pain Medicine VX-548 by Vertex Pharmaceuticals for Neuropathic Pain (Neuralgia): Likelihood of Approval VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. https://lnkd.in/e5SXsS7V

Neuronano is pioneering in highly specific Deep Brain Stimulation (DBS) therapy. We do this by optimizing the implantation process in addition to utilizing a controlled array of super thin electrodes that can be individually controlled. Neuronano’s DBS offers personalized therapy for Parkinson’s, tailored to the unique needs of each patient, with limited side effects. Normally, pharmaceutical care for Parkinson's disease, employing medications like levodopa and dopamine agonists, offers symptom relief but poses risks due to potential side effects. Common adverse reactions include dyskinesias, nausea, hallucinin compations, and motor fluctuations. Prolonged use, especially of levodopa, may lead to cognitive issues. Read more about our research at https://lnkd.in/gtm45A7

https://lnkd.in/dhXK2ct3 The Germany Depression Therapeutics Market, valued at USD 372 million in 2023, is positioned for steady growth, with a projected revenue surge at a CAGR of 3.7% from 2023 to 2030, reaching nearly USD 479 Million. The field of depression therapeutics in Germany holds high innovation potential, offering promising opportunities for research and development. The report emphasizes the significance of innovation in shaping the market landscape and addressing unmet needs in depression treatment. #maximizemarketresearch #GermanyDepressionTherapeutics #MentalHealth #InnovationInHealthcare #MarketGrowth #ResearchOpportunities #InvestmentAppeal #FutureOutlook #HealthcareInnovation #MentalWellness #DepressionTreatment #MarketAnalysis #MMRResearch

“𝗚𝗼𝗶𝗻𝗴 𝗯𝗲𝘆𝗼𝗻𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗮𝗰𝗶𝗱-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀.” Phathom Pharmaceuticals (NASDAQ: PHAT) is on a mission to revolutionize the treatment landscape for acid-related gastrointestinal (GI) disorders. With a commitment to advancing treatments and improving patients' lives, they're making significant strides in the biopharmaceutical world, especially for those suffering from GI diseases related to acid. Because when it comes to GI disorders, innovative and effective treatments are crucial! 🔗 Dive in: https://lnkd.in/eGkgjJVm #gastroentrology #PhathomPharma #SoHCSpotlights Slice of Healthcare

Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor This week: we look at EMA's updated draft Guideline for depression therapeutics, which includes a section on psychedelics; California's Governor is set to decide the fate of a state-wide decrim. bill, SB-58; MAPS published its second Phase 3 study; and lots more... https://lnkd.in/gN7hBZw9